Finance

Lists
CHRS:NASDAQ
Coherus Oncology Inc
1,07 US$
0,00%
(0,00) 1D
1,09 US$
+1,87% (+0,020)
After hours
Closed: 9 ოქტ, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CHRS...
Open
1,06 US$
High
1,12 US$
Low
1,05 US$
Mkt. cap
165,32 მლნ.
Avg. vol.
1,35 მლნ.
Volume
1,70 მლნ.
52-wk high
2,62 US$
52-wk low
0,97 US$
EPS
-1,03 US$
Beta
0,98
Shares outstanding
154,50 მლნ.
No. of employees
144
Open
1,06 US$
High
1,12 US$
Low
1,05 US$
Mkt. cap
165,32 მლნ.
Avg. vol.
1,35 მლნ.
Volume
1,70 მლნ.
52-wk high
2,62 US$
52-wk low
0,97 US$
EPS
-1,03 US$
Beta
0,98
Shares outstanding
154,50 მლნ.
No. of employees
144
News stories
From web sources and news partners
Yahoo Finance
Yahoo Finance
·
1 საათის წინ
A COVID Vaccine Stock on the S&P 500 Is Up 600% This Year
The Globe and Mail
The Globe and Mail
·
1 საათის წინ
Streamex Receives Nasdaq Notice on Minimum Bid Price
24/7 Wall St.
24/7 Wall St.
·
15 საათის წინ
Why "VOO and Chill" Lost Money for 8 Straight Years: What $100,000 in the S&P 500 Did From 2000 to 2008
Investor's Business Daily
Investor's Business Daily
·
6 საათის წინ
Futures: 6 Stocks Near Buy Points; Big Earnings, Inflation Data Due
About Coherus Oncology Inc
CEODennis Lanfear
Employees144
Founded2010
HeadquartersRedwood City, კალიფორნია, ამერიკის შეერთებული შტატები
Sector-
Websitecoherus.com
Analyst ratings
Based on 4 analysts giving stock ratings to CHRS in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for CHRS in the last 3 months.
Highest
Current 1,07 US$
10,00 US$ (+834,58%)
Average
7,75 US$ (+624,30%)
Lowest
4,00 US$ (+273,83%)
Analyst
Recommendation
Action
Price target
Projected
Date
Douglas Tsao
H.C. Wainwright
Buy
Reiterated
7,00 US$
+554,2%
09/21/2026
Jason McCarthy
Maxim Group
Buy
Maintained
4,00 US$
+273,8%
08/06/2026
Paul Jeng
Guggenheim
Buy
Maintained
10,00 US$
+834,6%
08/06/2026
Jay Olson
Oppenheimer
Buy
Maintained
10,00 US$
+834,6%
08/06/2026
Michael Nedelcovych
TD Cowen
Buy
Maintained
-
-
05/28/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
11,57 მლნ.
12,75 მლნ.
12,31 მლნ.
14,31 მლნ.
Cost of goods sold
3,72 მლნ.
4,04 მლნ.
3,81 მლნ.
4,24 მლნ.
Cost of revenue
3,72 მლნ.
4,04 მლნ.
3,81 მლნ.
4,24 მლნ.
Research and development expenses
27,25 მლნ.
30,97 მლნ.
21,54 მლნ.
21,45 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
22,83 მლნ.
21,01 მლნ.
23,10 მლნ.
20,95 მლნ.
Operating expense
50,08 მლნ.
51,98 მლნ.
44,65 მლნ.
42,40 მლნ.
Total operating expenses
53,80 მლნ.
56,03 მლნ.
48,46 მლნ.
46,64 მლნ.
Operating income
-42,23 მლნ.
-43,28 მლნ.
-36,15 მლნ.
-32,33 მლნ.
Other non operating income
2,14 მლნ.
-5,22 მლნ.
1,40 მლნ.
1,31 მლნ.
EBT including unusual items
-44,52 მლნ.
-46,35 მლნ.
-36,94 მლნ.
-33,35 მლნ.
EBT excluding unusual items
-42,42 მლნ.
-43,75 მლნ.
-36,94 მლნ.
-33,35 მლნ.
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-35,53 მლნ.
-37,64 მლნ.
-38,33 მლნ.
-20,63 მლნ.
Net profit margin
-307,07%
-295,29%
-311,35%
-144,20%
Earnings per share
-0,33
-0,34
-0,25
-0,19
Interest and investment income
-
7,00 მლნ.
-
-
Interest expense
-2,32 მლნ.
-2,25 მლნ.
-2,19 მლნ.
-2,32 მლნ.
Net interest expenses
-2,32 მლნ.
4,75 მლნ.
-2,19 მლნ.
-2,32 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-41,27 მლნ.
-42,38 მლნ.
-35,27 მლნ.
-31,47 მლნ.
Gain or loss from assets sale
-
-338,32 მლნ.
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები